Vaccine Clinical Trials
At NYU Langone’s Vaccine Center, the major goal of our scientists is to keep people healthy. We study how vaccines can prevent disease outbreaks by helping people’s natural immune systems fight infections such as the flu, measles, and COVID-19. We also study how to develop new vaccines for a wide range of illnesses, from autoimmune disorders to cancers.
In order to make sure that vaccines are safe and effective, we lead clinical trials, in which people volunteer to participate in a study that is testing a vaccine to make sure it’s working. If you volunteer to participate in a vaccine clinical trial, you are protected under the Participant Bill of Rights. In addition, you are part of an amazing collaborative effort to advance vaccine science and protect our communities from disease.
We invite you to join our registry, which is a database of potential volunteers for clinical trials. Our registry is open to both adults and children. If you join the registry, we may contact you to discuss your eligibility to participate in a trial.
If you have questions about participating in a vaccine clinical trial, please email us at firstname.lastname@example.org.
Active Clinical Studies—Enrollment Open
Our ongoing studies support future vaccine trials and studies of the human immune system and infectious diseases. This research builds on prior studies of the human immune response to infections and offers deeper insight into the complexity of these responses. It also holds possibilities for the development of rapid responses to emerging infectious threats.
A Study to Evaluate the Safety Tolerability and Immunogenicity of a Modified RNA (mRNA) Vaccine Against Influenza
This is a phase 3 randomized, blinded study to assess the safety, tolerability, and efficacy of a single dose of a study mRNA vaccine against flu in healthy individuals. Using an mRNA platform for the flu shot can quicken the manufacturing of the vaccine, which increases the likelihood that the vaccine matches the seasonal strains. Participants will be asked to complete up to five in-person clinic visits in Manhattan over a six-month period.
To Evaluate the Safety, Tolerability, Efficacy, and Immunogenicity of Self-Amplifying RNA Vaccine Preparations Against Influenza in Healthy Individuals
Enrolling at the Vaccine Center’s 660 First Avenue site, this phase 1, placebo-controlled, randomized, observer-blind, dose-finding study will evaluate the safety, tolerability, and immunogenicity of self-amplifying RNA vaccine preparations against influenza in healthy individuals.
COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)
Enrolling at the Vaccine Center’s 660 First Avenue and NYU Langone Hospital—Long Island sites, this phase 2 clinical trial will evaluate the safety and immunogenicity of additional doses of prototype and variant (alone or in combination) vaccine candidates in previously vaccinated participants with or without prior SARS-CoV-2 infection and will evaluate innate, cellular, and humoral immune responses to inform on how to shift the immune response to cover new variants as they emerge.
Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
Enrolling at the NYC Health + Hospitals/Bellevue and NYU Langone Hospital—Long Island satellite sites of the Vaccine Center.
To Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza in Healthy Individuals
Enrolling at the Vaccine Center’s 660 First Avenue site, this phase 1, placebo-controlled, randomized, observer-blind, dose-finding study will evaluate the safety, tolerability, and immunogenicity of modified RNA vaccine against influenza in healthy individuals.
Predicting Poor Vaccine Responders to Hepatitis B Vaccination
Enrolling at the Vaccine Center’s 660 First Avenue site, this study aims to understand how the immune system learns from the hepatitis B vaccine and why some people do not respond to the vaccine.
Phlebotomy of Healthy Adults for the Purpose of Evaluation and Validation of Immune Response and Microbiology Assays
Enrolling at the Vaccine Center’s 660 First Avenue site, the purpose of this study is to create a bank of different types of samples. Some of these samples might be used to develop and validate lab tests. These lab tests are intended to be used for biomedical research, vaccine studies, and studies of the human immune system. This is a specimen collection study. There is no intervention. The study serves to generate a biospecimen repository of samples from human volunteers for the purpose of evaluation and validation of new assays and to provide healthy control specimens for vaccine and infectious diseases studies.
Specimen Collection for Infectious Diseases with Public Health Importance
Enrolling at the Vaccine Center’s 660 First Avenue site, the purpose of this research study is to generate a biospecimen repository from human volunteers with suspected or confirmed, current, or past infectious disease of public health importance. The researchers will use your blood and other optional body fluid samples to develop and validate new assays (lab tests), vaccines, and diagnostic tests for treatment of infectious diseases that are being explored at the Vaccine Center.
Active Clinical Studies—Enrollment Closed
The following clinical studies are not enrolling participants at this time, but remain active. You can also view a list of past clinical trials to learn more about the scope of our work.
The Stop Flu NYU Cohort Study
Based at the Vaccine Center’s 660 First Avenue site, this study is being conducted to study the body’s response to the seasonal influenza vaccination and to learn about the protection from infection with influenza.
Controlled Study Comparing the Immune Response and Safety of a Research Yellow Fever Vaccine Candidate to a Licensed Yellow Fever Vaccine for Adults
This is a phase 2 yellow fever vaccine trial sponsored by Sanofi Pasteur comparing a research yellow fever vaccine to an FDA-licensed vaccine.